Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar latimerburned (92.85) Submitted: 1/19/2007 2:27:23 PM : Outperform Start Price: $9.00 EXEL Score: -57.22

One of the best oncology pipelines of any small biotech. They have the potential to be the next Genentech.

Featured Broker Partners


Advertisement